Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus UFOX vs FOLFOX-4 in first-line metastatic colorectal cancer
2006-000685-36Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Nov 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cetuximab in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Merck KGaA. Primary endpoint: Progression-free survival. Started Nov 2006; status: completed.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2006-000685-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000685-36.